Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Before they get COVID, people over 65 should have a plan for accessing antiviral treatment.
The antiviral treatment reduced the risk of hospitalization or death from SARS-CoV-2 Omicron variants in older adults by 44%.
The antiviral treatment is safe and effective for pediatric patients ages 12 and up.
Lack of access to treatment facilities may worsen these racial disparities.
The small study found no evidence of delayed development of antibodies in participants who experienced rebound after taking Paxlovid.
People with HIV are at greater risk for hepatitis B but are less likely to get vaccinated and respond to vaccines.
Remdesivir (Veklury) is now approved for kids ages 28 days to 12 years.
Paxlovid and molnupiravir can reduce the risk of severe COVID-19, but they must be started within five days of symptom onset.
Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.
Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.
The new drugs must be used within a narrow window of time after developing symptoms.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
Paxlovid dramatically reduced the risk of severe illness and death, but it must be started soon after developing symptoms.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
People under 50 who were cured of hepatitis C were at comparable risk to the general population.
Assessing patient-reported outcomes can support treatment for hard-to-reach populations.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.